NY AG Letitia James calls for FDA to address potential dangers of asthma and allergy drug Singulair
In a letter to the FDA commissioner, James wrote the drug has been linked to harmful behavioral and mental health issues among children.
•
Feb 26, 2024, 10:29 PM
•
Updated 268 days ago
Share:
More Stories
1:37
Local doctors see uptick in respiratory illnesses, specifically walking pneumonia
29ds ago0:29
Former flight attendant honors 9/11 heroes with 200-mile tribute
72ds ago0:42
Building partially collapses in Mount Vernon, shuts down parts of street
105ds ago0:57
School bus driver training held in Ramapo
105ds ago0:32
Family of Dutchess County explorer who died in OceanGate submersible files wrongful death lawsuit
105ds ago1:42
Firefighters battle blaze in extreme heat in Verplanck
128ds ago1:37
Local doctors see uptick in respiratory illnesses, specifically walking pneumonia
29ds ago0:29
Former flight attendant honors 9/11 heroes with 200-mile tribute
72ds ago0:42
Building partially collapses in Mount Vernon, shuts down parts of street
105ds ago0:57
School bus driver training held in Ramapo
105ds ago0:32
Family of Dutchess County explorer who died in OceanGate submersible files wrongful death lawsuit
105ds ago1:42
Firefighters battle blaze in extreme heat in Verplanck
128ds agoThe New York Attorney General Letitia James is calling on the FDA to address the potential dangers of popular asthma and allergy medication Singulair.
In a letter to the FDA commissioner, James wrote the drug has been linked to harmful behavioral and mental health issues among children.
Multiple parents have reported their children having aggressive behavior, intense nightmares and depression while using the drug.
Some even had suicidal thoughts or committed suicide, James wrote in the letter.
The FDA issued a black box warning for Singulair in March 2020 for the same reasons.
